225 related articles for article (PubMed ID: 31819055)
21. Indirect Down-regulation of Tumor-suppressive
Saeki N; Saito A; Sugaya Y; Amemiya M; Sasaki H
Cancer Genomics Proteomics; 2018; 15(5):413-420. PubMed ID: 30194082
[TBL] [Abstract][Full Text] [Related]
22. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
23. MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.
Lu F; Mu B; Jin G; Zhu L; Mu P
Oncol Res; 2022 May; 29(1):1-10. PubMed ID: 34937609
[TBL] [Abstract][Full Text] [Related]
24. The proneural transcription factor ASCL1 regulates cell proliferation and primes for differentiation in neuroblastoma.
Parkinson LM; Gillen SL; Woods LM; Chaytor L; Marcos D; Ali FR; Carroll JS; Philpott A
Front Cell Dev Biol; 2022; 10():942579. PubMed ID: 36263020
[TBL] [Abstract][Full Text] [Related]
25. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
[TBL] [Abstract][Full Text] [Related]
26. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
27. LncRNA SNHG1 regulates neuroblastoma cell fate via interactions with HDAC1/2.
Hsu CL; Yin CF; Chang YW; Fan YC; Lin SH; Wu YC; Huang HC; Juan HF
Cell Death Dis; 2022 Sep; 13(9):809. PubMed ID: 36130928
[TBL] [Abstract][Full Text] [Related]
28. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
[TBL] [Abstract][Full Text] [Related]
29. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
30. SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.
Hu X; Liu R; Hou J; Peng W; Wan S; Xu M; Li Y; Zhang G; Zhai X; Liang P; Cui H
Oncogene; 2022 Sep; 41(37):4295-4306. PubMed ID: 35978151
[TBL] [Abstract][Full Text] [Related]
31. Upregulated LMO1 in prostate cancer acts as a novel coactivator of the androgen receptor.
Gu H; Liu T; Cai X; Tong Y; Li Y; Wang C; Li F
Int J Oncol; 2015 Dec; 47(6):2181-7. PubMed ID: 26459575
[TBL] [Abstract][Full Text] [Related]
32. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
33. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
[TBL] [Abstract][Full Text] [Related]
34. Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.
Murphy DM; Buckley PG; Das S; Watters KM; Bryan K; Stallings RL
PLoS One; 2011; 6(6):e21436. PubMed ID: 21731748
[TBL] [Abstract][Full Text] [Related]
35. Ascl1 phospho-status regulates neuronal differentiation in a Xenopus developmental model of neuroblastoma.
Wylie LA; Hardwick LJ; Papkovskaia TD; Thiele CJ; Philpott A
Dis Model Mech; 2015 May; 8(5):429-41. PubMed ID: 25786414
[TBL] [Abstract][Full Text] [Related]
36. LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors.
Tao T; Shi H; Mariani L; Abraham BJ; Durbin AD; Zimmerman MW; Powers JT; Missios P; Ross KN; Perez-Atayde AR; Bulyk ML; Young RA; Daley GQ; Look AT
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16516-16526. PubMed ID: 32601179
[TBL] [Abstract][Full Text] [Related]
37. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
38. A transcription factor network specifying inhibitory versus excitatory neurons in the dorsal spinal cord.
Borromeo MD; Meredith DM; Castro DS; Chang JC; Tung KC; Guillemot F; Johnson JE
Development; 2014 Jul; 141(14):2803-12. PubMed ID: 24924197
[TBL] [Abstract][Full Text] [Related]
39. LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy.
Zhang Y; Yang J; Wang J; Guo H; Jing N
Med Oncol; 2014 Aug; 31(8):99. PubMed ID: 25037573
[TBL] [Abstract][Full Text] [Related]
40. Shutdown of achaete-scute homolog-1 expression by heterogeneous nuclear ribonucleoprotein (hnRNP)-A2/B1 in hypoxia.
Kasim M; Benko E; Winkelmann A; Mrowka R; Staudacher JJ; Persson PB; Scholz H; Meier JC; Fähling M
J Biol Chem; 2014 Sep; 289(39):26973-26988. PubMed ID: 25124043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
